Bicara Therapeutics Common Stock Net Income

Bicara Therapeutics Common Stock's net income stands at $-190M as of June 2026. That compares with $-100M in the prior-year period — down 80.5% year over year. That is below the Healthcare sector average of $16B. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Bicara Therapeutics Common Stock reported $-190M in net income versus $-100M a year earlier — a 80.5% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

Bicara Therapeutics Common Stock sits lower the Healthcare benchmark ($16B) with a net income of $-190M. That is roughly 101.1% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

That compares with $-100M in the prior-year period — down 80.5% year over year. Sustained growth in net income can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Bicara Therapeutics Common Stock's net income evolved across reporting periods, while the comparison chart places BCAX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.